In the News

In the Literature – November 2016

November 2016, Vol 7, No 10 - In the Literature

  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Adding Daratumumab to Standard Regimen Extends Progression-Free Survival in Patients with Multiple Myeloma
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]

FDA News – November 2016

November 2016, Vol 7, No 10 - FDA News & Updates

  • Tecentriq Approved by the FDA for Metastatic NSCLC
  • Keytruda Receives New FDA Indication for First-Line Treatment of Metastatic NSCLC
  • Lartruvo First Drug in 40 Years to Receive FDA Approval for Soft-Tissue Sarcoma
  • FDA Revises the Indication for Tarceva for Treatment of NSCLC
  • FDA Awards $23 Million Worth of Grants to Encourage Drug Development for Rare Diseases
[ Read More ]

FDA News – October 2016

October 2016, Vol 7, No 9 - FDA News & Updates

In This Article Dosage Regimen for Nivolumab Modified Use of Screening Tests for Ovarian Cancer Not Supported by the FDA Dosage Regimen for Nivolumab Modified On September 13, 2016, the FDA modified the dosage regimen of nivolumab (Opdivo) for the treatment of patients with renal-cell carcinoma, metastatic melanoma, and non–small-cell lung cancer (NSCLC) to 240 mg intravenously (IV) every [ Read More ]

In the Literature – October 2016

October 2016, Vol 7, No 9 - In the Literature

In This Article Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma Addition of Elective Neck Dissection Reduces Overall Costs in Patients with Oral Cavity Cancer 70-Gene Signature Assists Clinicians in Breast Cancer Treatment Decision-Making Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Many patients with B-cell acute lymphoblastic leukemia (ALL) who achieve complete remission will have disease relapse. Because of the poor prognosis for adults with relapsed ALL, investigators assessed the efficacy and safety [ Read More ]

Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

September 2016, Vol 7, No 8 - Drug Updates

Urothelial carcinoma (also known as transitional-cell carcinoma) is the most common subtype of bladder cancer, accounting for more than 90% of bladder cancer diagnoses in the United States. In 2016, nearly 77,000 cases of bladder cancer are expected to be diagnosed in the United States, and more than 16,000 people will die from this disease. The incidence of bladder cancer increases with age, with a median age of 73 years at diagnosis. [ Read More ]